According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the U.S. market for diagnostic imaging equipment servicing will grow slowly to a value of just over $2.78 billion by 2017. Increases in diagnostic imaging system sales and the installed base will be counterbal



http://glossary.itnonline.com/3d-mammographyHologic Inc. announced that a groundbreaking new study published in Radiology, the Radiological Society of North America scientific journal, found that the addition of three dimensional (3-D) mammography (breast tomosynthesis) screening technology to a 2-D breast screening exam significantly increased cancer detection while reducing the number of false positives.



January 11, 2013 — New guidelines from the American Cancer Society say there is now sufficient evidence to recommend screening high-risk patients for lung cancer with low-dose computed tomography (LDCT), provided that certain conditions exist.


Availability of CT colonography (CTC), commonly known as virtual colonoscopy, is increasing colorectal cancer (CRC) screening rates across military medical facilities. Inclusion of CTC as a Healthcare Effectiveness Data and Information Set (HEDIS)-compliant colorectal cancer (CRC) screening test can potentially raise overall screening rates, according to a study in the January issue of the Journal of the American College of Radiology.

In the management of gliomas — or tumors that originate in the brain — precise assessment of tumor grade and the proliferative activity of cells plays a major role in determining the most appropriate treatment and predicting overall survival. Research published in the December issue of The Journal of Nuclear Medicine (JNM) highlights the potential of imaging with 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) positron emission tomography (PET) to noninvasively and accurately provide tumor-specific details to guide management of patients with gliomas.


According to a new market research report "Breast Imaging Technologies Market (Digital Mammography,3D Breast Tomosynthesis, Breast MRI, Breast Ultrasound, Molecular Breast Imaging, Optical Imaging, PET/CT/PEM Modalities) Technology and Market Analysis & Global Forecasts to 2017" is an attempt to showcase the market impact of current and emerging breast imaging technologies having excellent growth potential in the coming five years. The technologies profiled in the report are segmented into Ionizing breast imaging modalities and Non-Ionizing breast imaging technologies on basis of radiation. Ionizing breast imaging modalities include Mammography, 3D Breast Tomosynthesis, Cone beam Computed Tomography (CBCT), Positron Emission Mammography (PEM), Molecular Breast Imaging (MBI), Positron Emission Tomography (PET) and Breast Specific Gamma Imaging (BSGI). The various Non-ionizing modalities for breast screening covered in the report are Breast MRI, Optical Imaging, Breast thermography and Breast Ultrasound.


Royal Philips Electronics today announced a landmark agreement with the Farah Medical Complex in Jordan that will see the development of a new hospital which has patient experience firmly at the center of its ethos. Through this partnership, Philips will provide a customized package of 15 advanced imaging solution systems, healthcare informatics and services, in addition to a suite of 20 Ambient Experience rooms, the largest installation to date in any hospital worldwide.

Bayer HealthCare announced that the company has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

Avreo announced that KLAS, an independently owned and operated healthcare technology research organization, has ranked Avreo interWORKS 1st for Radiology (Community) in the “2012 Best in KLAS Awards: Software & Services” report for the second year in a row. Avreo’s interWORKS product earned a high score of 90.9 out of 100 with a 100 percent of participators saying they would buy the Avreo solution again.

iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced approval by the U.S. Food and Drug Administration (FDA) for use of the company’s next generation mammography computer-aided detection (CAD) platform, PowerLook Advanced Mammography Platform (AMP), with Digital CAD for Philips’ MicroDose Full-Field Digital Mammography System.

Subscribe Now